Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis

任天堂 吡非尼酮 医学 特发性肺纤维化 内科学 肺活量 荟萃分析 胃肠病学 肿瘤科 扩散能力 肺功能
作者
James Finnerty,Aravind Ponnuswamy,Prosjenjit Dutta,Ammar Abdelaziz,H G Kamil
出处
期刊:BMC Pulmonary Medicine [Springer Nature]
卷期号:21 (1) 被引量:81
标识
DOI:10.1186/s12890-021-01783-1
摘要

Abstract Background Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of anti-fibrotic therapy (grouping nintedanib and pirfenidone together) in patients with IPF versus patients with progressive lung fibrosis not classified as IPF. Study design and methods A search of databases including MEDLINE, EMBASE, PubMed, and clinicaltrials.gov was conducted. Studies were included if they were randomised controlled trials of pirfenidone or nintedanib in adult patients with IPF or non-IPF patients, and with extractable data on mortality or decline in forced vital capacity (FVC). Random effects meta-analyses were performed on changes in FVC and where possible on mortality in the selected studies. Results 13 trials of antifibrotic therapy were pooled in a meta-analysis (with pirfenidone and nintedanib considered together as anti-fibrotic therapy). The change in FVC was expressed as a standardised difference to allow pooling of percentage and absolute changes. The mean effect size in the IPF studies was − 0.305 (SE 0.043) ( p < 0.001) and in the non-IPF studies the figures were − 0.307 (SE 0.063) ( p < 0.001). There was no evidence of any difference between the two groups for standardised rate of FVC decline ( p = 0.979). Pooling IPF and non-IPF showed a significant reduction in mortality, with mean risk ratio of 07.01 in favour of antifibrotic therapy ( p = 0.008). A separate analysis restricted to non-IPF did not show a significant reduction in mortality (risk ratio 0.908 (0.547 to 1.508), p = 0.71. Interpretation Anti-fibrotic therapy offers protection against the rate of decline in FVC in progressive lung fibrosis, with similar efficacy shown between the two anti-fibrotic agents currently in clinical use. There was no significant difference in efficacy of antifibrotic therapy whether the underlying condition was IPF or non-IPF with progressive fibrosis, supporting the hypothesis of a common pathogenesis. The data in this analysis was insufficient to be confident about a reduction in mortality in non-IPF with anti-fibrotic therapy. Trial Registration PROSPERO, registration number CRD42021266046.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
杨冰完成签到,获得积分10
2秒前
2秒前
方成元完成签到,获得积分10
2秒前
3秒前
zxy发布了新的文献求助10
3秒前
SYLH应助乐观荔枝采纳,获得10
3秒前
ZXMF72号发布了新的文献求助10
4秒前
chi发布了新的文献求助10
4秒前
4秒前
52Hz完成签到,获得积分10
4秒前
Akim应助1234567采纳,获得10
4秒前
5秒前
打打应助123采纳,获得10
6秒前
科目三应助拽根大恐龙采纳,获得10
6秒前
西八完成签到,获得积分10
6秒前
欢喜的雁枫应助7777777采纳,获得10
7秒前
8秒前
直率黑夜发布了新的文献求助10
9秒前
成就雨筠应助铁匠采纳,获得10
9秒前
hx发布了新的文献求助10
9秒前
华仔应助科研通管家采纳,获得10
10秒前
所所应助科研通管家采纳,获得10
10秒前
领导范儿应助科研通管家采纳,获得10
10秒前
星辰大海应助科研通管家采纳,获得10
10秒前
科研通AI5应助科研通管家采纳,获得10
10秒前
我是老大应助科研通管家采纳,获得10
10秒前
10秒前
烟花应助科研通管家采纳,获得10
10秒前
CodeCraft应助科研通管家采纳,获得10
10秒前
SciGPT应助科研通管家采纳,获得10
10秒前
斯文败类应助科研通管家采纳,获得10
10秒前
Catalina_S应助科研通管家采纳,获得60
10秒前
11秒前
科研通AI2S应助王广发得得采纳,获得10
11秒前
phoebe完成签到,获得积分10
11秒前
舒适的善若完成签到,获得积分10
12秒前
12秒前
12秒前
执念完成签到 ,获得积分10
12秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Kelsen’s Legacy: Legal Normativity, International Law and Democracy 1000
Handbook on Inequality and Social Capital 800
Conference Record, IAS Annual Meeting 1977 610
Interest Rate Modeling. Volume 3: Products and Risk Management 600
Interest Rate Modeling. Volume 2: Term Structure Models 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3546888
求助须知:如何正确求助?哪些是违规求助? 3123917
关于积分的说明 9357332
捐赠科研通 2822504
什么是DOI,文献DOI怎么找? 1551513
邀请新用户注册赠送积分活动 723546
科研通“疑难数据库(出版商)”最低求助积分说明 713791